

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Raymond Ruddon, M.D., Ph.D.	POSITION TITLE Professor Emeritus
eRA COMMONS USER NAME (credential, e.g., agency login) RRUDDON	

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)

INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
University of Detroit, Detroit, MI	B.S.	1958	Chemistry (Summa cum laude)
University of Michigan, Ann Arbor, MI	Ph.D.	1964	Pharmacology
University of Michigan, Ann Arbor, MI	M.D.	1967	

A. Positions and Honors

Positions and Employment

- 2006 – present Professor Emeritus, Department of Pharmacology, University of Michigan Medical School
- 2004 – 2006 Sr. Associate Dean for Research & Graduate Studies, Univ. of Michigan Medical School
- 2003 – 2004 Distinguished Fellow, Corporate Office of Science & Technology, Johnson & Johnson
- 2000 – 2003 Corporate Vice President, Science & Tech., and Chief Scientific Officer, Johnson & Johnson
- 1997 – 2000 Corp. Director, Science & Tech., Johnson & Johnson Corp., Office of Science & Technology
- 1998 – 2004 Adjunct Professor of Pharmacology, UMDNJ-Robert Wood Johnson Medical School
- 1993 – 1997 Director, UNMC/Eppley Cancer Center
- 1990 – 1997 Director and Eppley Professor of Oncology, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center
- 1988 – 1990 Maurice H. Seevers Professor of Pharmacology, Univ. of Michigan Medical School
- 1986 – 1990 Assoc. Director for Basic Science Research, Univ. of Michigan Comprehensive Cancer Ctr.
- 1981 – 1990 Professor and Chairman, Department of Pharmacology, Univ. of Michigan Medical School
- 1976 – 1981 Director, Biological Markers Program, National Cancer Institute, Frederick Cancer Research Center
- 1974 – 1976 Professor of Pharmacology, University of Michigan Medical School
- 1969 – 1974 Associate Professor of Pharmacology, University of Michigan Medical School
- 1967 – 1969 Asst. Professor of Pharmacology, University of Michigan Medical School
- 1964 – 1967 Instructor of Pharmacology, University of Michigan Medical School

Awards, Honors, Special Recognition

- 1958 American Chemical Society Award
- 1964 Phi Beta Kappa, University of Michigan
- 1964 – 1967 Postdoctoral Scholar of the American Cancer Society
- July 1988 Keynote Lecturer, 8th International Congress of Endocrinology, Satellite Symposium on Placental Protein Hormones, Kobe, Japan
- 1988 Sterling-Sullivan Visiting Professor of Pharmacology, Morehouse School of Medicine
- 1988 Distinguished Faculty Achievement Award, University of Michigan
- May 1989 Keynote Lecturer, International Symposium on Structure-Function Relationship of Gonadotropins, Paris, France
- March 1993 Co-Chair, International Serono Symposium on Glycoprotein Hormones: Structure, Function, and Clinical Applications, Santa Barbara, CA
- 1993 Outstanding Alumni Award, Department of Pharmacology, Univ. of Michigan Medical School
- Editor, Chemotherapy Chapters, ninth edition of Goodman and Gilman's The Pharmacological Basis of Therapeutics

March 1997 Invited Lecturer, Keystone Symposium on Molecular and Cellular Biology: Protein Folding, Modification, and Transport in the Early Secretory Pathway, Taos, NM
2002 Distinguished Achievement Award, Univ. of Michigan Medical Center Alumni Society

B. Selected publications (in chronological order)

Ruddon, R.W., (ed.) Biological Markers of Neoplasia: Basic & Applied Aspects. Elsevier North Holland, New York, 1978, 590 pages.
Pratt W.B., R.W. Ruddon. The Anticancer Drugs. Oxford University Press, New York, 1979, 323 pages.
Ruddon R.W. Cancer Biology. Oxford University Press, New York, 1981, 344 pages.
Ruddon R.W. Cancer Biology. Oxford University Press, New York, Second Edition, 1987, 530 pages.
Pratt W.B., R.W. Ruddon, J. Maybaum, W.D. Ensminger. The Anticancer Drugs. Oxford University Press, New York, Second Edition, 1994, 352 pages.
Ruddon R.W. Cancer Biology. Oxford University Press, New York, Third Edition, 1995, 520 pages.
Ruddon R.W. Cancer Biology. Oxford University Press, New York, Fourth Edition, 2007, 530 pages.
Ruddon, R.W. (ed.) Molecular Biology of Cancer: Translation to the Clinic, Volume 95, Progress in Molecular Biology and Translational Science, Academic Press/Elsevier, 2010, 386 pages.

Publications in Scientific Journals (of 101)

Sherman, S.A., W.H. Gmeiner, L., Kirnarskiy, F. Perini, and R.W. Ruddon. A linear 23-residue peptide reveals a propensity to form an unusual native-like conformation. *J. Biomol. Structure and Dynamics*, 13:441-446, 1995.
Ruddon, R.W., S.A. Sherman, and E. Bedows. Protein folding in the endoplasmic reticulum: Lessons from the human chorionic gonadotropin β subunit. *Protein Science*, 5:1443-1452, 1996.
Feng, W., E. Bedows, S.E. Norton, and R.W. Ruddon. Novel covalent chaperone complexes associated with human chorionic gonadotropin β subunit folding intermediates. *J. Biol. Chem.*, 271:18543-18548, 1996.
Ruddon, R.W. Super hormones. *Nature Biotechnology*, 14:1224, 1996.
Bishop, M.R., P.L. Iversen, E. Bayever, J.G. Sharp, T. Greiner, B.L. Copple, R.W. Ruddon, G. Zon, J. Spinolo, M. Arneson, J.O. Armitage, and A. Kessinger. Phase I Trial of an Antisense Oligonucleotide OL(1) p53 in Hematologic Malignancies. *J. Clin. Oncol.* 14:1320-1326, 1996.
Ruddon, R.W. and E. Bedows. Assisted Protein Folding. *J. Biol. Chem.*, 272:3125-3128, 1997.
Miller-Lindholm, A. K., C.J. LaBenz, J. Ramey, E. Bedows, and R.W. Ruddon. Human Chorionic Gonadotropin- β Gene Expression in First Trimester Placenta. *Endocrinology*, 138:5459-5465, 1997.
Muyan, M., R.W., Ruddon, S.E. Norton, I. Boime, and E. Bedows. Dissociation of Early Folding Events from Assembly of the Human Lutropin β -Subunit. *Molecular Endocrinology*, 12:1640-1649, 1998.
Miller-Lindholm, A.K., E. Bedows, C.F. Bartels, J. Ramey, V. Maclin, and R.W. Ruddon. A Naturally Occurring Genetic Variant in the Human Chorionic Gonadotropin- β Gene is Assembly Inefficient. *Endocrinology*, 140:3496-3506, 1999.
Darling, R.J., R.W. Ruddon, F. Perini, E. Bedows. Cystine knot mutations affect the folding of the glycoprotein hormone α -subunit. *J. Biol. Chem.*, 275:15413-15421, 2000.
Darling, R.J., J.A. Wilken, R.W. Ruddon and E. Bedows. Intracellular folding pathway of the cystine knot-containing glycoprotein hormone α subunit. *Biochemistry*. 40:577-585, 2001.
Darling, R.J., J.A. Wilken, A.K. Miller-Lindholm, T.M. Urlacher, R.W. Ruddon, S.A. Sherman, and E. Bedows. Functional contributions of non-cysteine residues within the cystine knots of human chorionic gonadotropin subunits. *J. Biol. Chem.* 276:10692-10699, 2001.
Kelloff, G.J., R.C. Bast, Jr., D.S. Coffey, A.V. D'Amico, R.S. Kerbel, J.W. Park, R.W. Ruddon G.J.S. Rustin, R.L. Schilsky, C.C. Sigman, G.F. Vande Woude. Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: An update. *Clinical Cancer Research*, 10:3881-3884, 2004.
Park, J.W., R.S. Kerbel, G.J. Kelloff, J.C. Barrett, B.A. Chabner, D.R. Parkinson, J. Peck, R.W. Ruddon, C.C. Sigman, D.J. Slamon. Rationale for biomarkers and surrogate endpoints in mechanism-driven oncology drug development. *Clinical Cancer Research*, 10:3885-3896, 2004.

Program Director/Principal Investigator (Last, First, Middle): Hayes, Daniel F.

Vande Woude, G.F., G.J.Kelloff, R.W. Ruddon H.M. Koo, C.C. Sigman, J.C. Barrett, R.W. Day, A.P. Dicker, R.S. Kerbel, D.R. Parkinson, W.J. Slichenmyer. Reanalysis of cancer drugs: old drugs, new tricks. *Clinical Cancer Research*, 10:3897-3907, 2004.

Rustin, G.J.S., R.C. Bast, Jr., G.J. Kelloff, J.C. Barrett, S.K. Carter, P.D. Nisen, D.R. Parkinson, R.W. Ruddon. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. *Clinical Cancer Research*, 10:3919-3926, 2004.

C. Previous Research Support

Source and Identifying no.: NCI, 2P30 CA36727-12

Principal Investigator: Raymond Ruddon

Title: Laboratory Cancer Research Center Support (CORE) Grant

Dates of entire project: 8/28/95 – 7/31/99

Major goals: The purpose of the CORE grant is to provide a base of financial support for the research and educational programs of the Eppley Institute.

Source and identifying no.: ACS, SIG-16A

Principal Investigator: Raymond Ruddon

Title: Cancer Cause and Prevention

Dates of the entire project: 1/1/92-12/31/96

Major goals: This is an ACS Core grant to fund investigators in cancer cause and prevention.

Source and identifying no.: NIH, 5T32 CA09476-07

Principal Investigator: Raymond Ruddon

Title: Cancer Biology Training Program

Dates of the entire project: 7/1/94-4/30/97

Major goals: This application is a training program for pre and postdoctoral students in oncology.

Source and identifying no.: NIH, 5:R01 CA32949-18

Principal Investigator: Raymond Ruddon

Title: Structural Determinants of hCG Folding and Assembly

Dates of entire project: 6/15/95-3/31/00

Major goals: Study of rate-limiting events in hCG production in tumor cells and normal placenta.